非霍奇金淋巴瘤(NHL)是来源于造血淋巴组织、异质性非常强的一类肿瘤。目前NHL的诊断主要依据组织病理学结果，而此并不能反映肿瘤负荷、侵袭能力和浸润程度以及治疗的反应等。所以，biomarker在淋巴瘤的早期诊断、监测治疗、疗效评价、预后和预测复发中有着重要的意义。Warburg效应指出肿瘤组织的代谢明显增强。因此从代谢角度发现biomarker，研究其在NHL治疗中作用具有重要临床价值。本课题拟首先以细胞株作为研究模型，按照其代谢特性分为不同的代谢类型。采用自主制备的PCR芯片和代谢组学筛选出能够代表各个代谢类型的biomarkers 1及耐药的biomarkers 2。应用PCR芯片检测临床肿瘤样品并依据biomarker将其分类、预测是否耐药。根据临床治疗方案和预后，得到肿瘤代谢类型与治疗方案预后、复发的相关性及耐药性预测的准确性。该研究成果有望为更有效的用药方案提供参考依据。

Non Hodgkin's lymphoma (NHL) is derived from hematopoietic lymphoid tissue and has heterogeneity. At present, the diagnosis of NHL is mainly based on the histopathological results, but this does not reflect the tumor burden, invasion, infiltration and treatment response. Therefore, some biomarkers play an important role in the early diagnosis of lymphoma, monitoring the treatment, therapeutic effect, prognosis and predictor of relapse. Warburg effect showed tumor tissue metabolism significantly enhanced. Therefore, based on metabolism to evaluate the therapeutic effect of NHL and prognosis has important clinical value. This project begins with the cells as the research model, according to the metabolic characteristics classify cell lines into different types. By prepared PCR array and metabolomics, we can screen out the biomarkers 1 and biomarkers 2, for classification and prediction of drug resistance respectively. Then，the prepared PCR array detect the clinical tumor samples, based on the biomarkers to classify and predict drug resistance. Finally, according to clinical treatment and outcome, we can obtain the relativity between tumor metabolic type and prognosis, recurrence. The biomarkers (prepared PCR array) may an extremely powerful tool used to diagnosis, monitor progress and prognosis cancer, and ultimately use them to build the evidence base needed to guide clinical practice.